 This Phase I study is designed to determine the excretion balance of radiocarbon, as the sum of carbon-14 14C-labeled TRO19622 and its 14C-metabolites, and to investigate the pharmacokinetics and metabolic profile of TRO19622 olesoxime in healthy participants. 